Show simple item record

dc.contributor.authorStinchcombe, Thomas E.
dc.contributor.authorHodgson, Lydia
dc.contributor.authorHerndon, James E. 2nd
dc.contributor.authorKelley, Michael J.
dc.contributor.authorCicchetti, M. Giulia
dc.contributor.authorRamnath, Nithya
dc.contributor.authorNiell, Harvey B.
dc.contributor.authorAtkins, James N.
dc.contributor.authorAkerley, Wallace
dc.contributor.authorGreen, Mark R.
dc.contributor.authorVokes, Everett E.
dc.date2022-08-11T08:10:32.000
dc.date.accessioned2022-08-23T17:12:21Z
dc.date.available2022-08-23T17:12:21Z
dc.date.issued2009-09-01
dc.date.submitted2017-04-19
dc.identifier.citationJ Thorac Oncol. 2009 Sep;4(9):1117-25. doi: 10.1097/JTO.0b013e3181b27b33. <a href="https://doi.org/10.1097/JTO.0b013e3181b27b33">Link to article on publisher's site</a>
dc.identifier.issn1556-0864 (Linking)
dc.identifier.doi10.1097/JTO.0b013e3181b27b33
dc.identifier.pmid19652624
dc.identifier.urihttp://hdl.handle.net/20.500.14038/46485
dc.description.abstractBACKGROUND: In Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would result in improved survival and demonstrated no significant benefit from the addition of induction chemotherapy. The primary objective of this analysis was to dichotomize patients into prognostic groups using factors predictive of survival and to investigate whether induction chemotherapy was beneficial in either prognostic group. PATIENTS AND METHODS: A Cox proportional hazard model was used to assess the impact on survival of the following factors: (>or=70 versus <70 years), gender, race, stage (IIIB versus IIIA), hemoglobin (hgb) (<13 versus >or=13 g/dl), performance status (PS) (1 versus 0), weight loss (>or=5% versus <5%), treatment arm, and the interaction between weight loss and hgb. RESULTS: Factors predictive of decreased survival were weight loss >or=5%, age >or=70 years, PS of 1, and hgb <13 g/dl (p < 0.05). Patients were classified as having >or=2 poor prognostic factors (n = 165) or or=2 versus patients with or=2 factors (HR = 0.86, 95% CI, 0.63-1.17; p = 0.34) or CONCLUSIONS: There is no evidence that induction chemotherapy is beneficial in either prognostic group.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19652624&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778485/
dc.subjectHealth Services Administration
dc.subjectNeoplasms
dc.subjectOncology
dc.subjectRadiology
dc.titleTreatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer
dc.typeJournal Article
dc.source.journaltitleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
dc.source.volume4
dc.source.issue9
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/qarc/37
dc.identifier.contextkey10042082
html.description.abstract<p>BACKGROUND: In Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would result in improved survival and demonstrated no significant benefit from the addition of induction chemotherapy. The primary objective of this analysis was to dichotomize patients into prognostic groups using factors predictive of survival and to investigate whether induction chemotherapy was beneficial in either prognostic group.</p> <p>PATIENTS AND METHODS: A Cox proportional hazard model was used to assess the impact on survival of the following factors: (>or=70 versus <70 years), gender, race, stage (IIIB versus IIIA), hemoglobin (hgb) (<13 versus >or=13 g/dl), performance status (PS) (1 versus 0), weight loss (>or=5% versus <5%), treatment arm, and the interaction between weight loss and hgb.</p> <p>RESULTS: Factors predictive of decreased survival were weight loss >or=5%, age >or=70 years, PS of 1, and hgb <13 g/dl (p < 0.05). Patients were classified as having >or=2 poor prognostic factors (n = 165) or or=2 versus patients with or=2 factors (HR = 0.86, 95% CI, 0.63-1.17; p = 0.34) or</p> <p>CONCLUSIONS: There is no evidence that induction chemotherapy is beneficial in either prognostic group.</p>
dc.identifier.submissionpathqarc/37
dc.contributor.departmentDepartment of Radiation Oncology
dc.contributor.departmentQuality Assurance Review Center
dc.source.pages1117-25


This item appears in the following Collection(s)

Show simple item record